XL 313

Drug Profile

XL 313

Alternative Names: XL313

Latest Information Update: 26 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Southern California
  • Developer Cell Matrix
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 05 May 2006 CancerVax Corporation merged with Micromet AG to form Micromet Inc
  • 25 Nov 2005 No development reported - Preclinical for Cancer in USA (Injection)
  • 15 Nov 2005 Eyetech Pharmaceuticals has been acquired by OSI Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top